Track Ultragenyx Pharmaceutical Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Ultragenyx Pharmaceutical Inc. RARE · Stock Open Ultragenyx Pharmaceutical Inc. in new tab

16.08 USD
EPS
-5.17
P/B
-4.40
ROE
-608.47
Beta
0.36
Target Price
25.35 USD
Loading chart...
Key Metrics
Earnings dateFeb. 11, 2027
EPS-5.17
Book Value-3.70
Price to Book-4.40
Debt/Equity5341.38
% Insiders3.320%
Growth
Revenue Growth0.08%
Estimates
Forward P/E11.36
Forward EPS1.43
Target Mean Price25.35

DCF valuation

Model fair value for Ultragenyx Pharmaceutical Inc. (RARE)
Result
Sign in to run the valuation for RARE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
20 analysts · consensus Buy · mean target 25.35 USD (low 16.00, high 39.00) · as of 12 Nov 2026
Low 16.00
Mean 25.35
High 39.00
Price 16.08
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Ultragenyx Pharmaceutical Inc. Logo Ultragenyx Pharmaceutical Inc. Analysis (RARE)

United States Health Care Official Website Stock

Is Ultragenyx Pharmaceutical Inc. a good investment? Ultragenyx Pharmaceutical Inc. (RARE) is currently trading at 16.08 USD. Market analysts have a consensus price target of 25.35 USD. This suggests a potential upside from current levels.

Earnings Schedule: Ultragenyx Pharmaceutical Inc. is expected to release its next earnings report on Feb. 11, 2027. The market consensus estimate for Forward EPS is 1.43.

Investor FAQ

Does Ultragenyx Pharmaceutical Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Ultragenyx Pharmaceutical Inc.?

Ultragenyx Pharmaceutical Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 11, 2027. The company currently has a trailing EPS of -5.17.

Company Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Exchange Ticker
FRA (Germany) UP0.F
STU (Germany) UP0.SG
NMS (United States) RARE
LSE (United Kingdom) 0LIF.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion